kynurenic acid has been researched along with Epilepsy in 33 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0." | 8.12 | Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022) |
| "Kynurenic acid is an endogenous modulator of ionotropic glutamate receptors and a suppressor of the immune system." | 5.56 | Sensitivity of Rodent Microglia to Kynurenines in Models of Epilepsy and Inflammation In Vivo and In Vitro: Microglia Activation is Inhibited by Kynurenic Acid and the Synthetic Analogue SZR104. ( Dulka, K; Földesi, I; Fülöp, F; Gulya, K; Kata, D; Lajkó, N; Mátyás, A; Mihály, A; Szabó, M; Vécsei, L, 2020) |
| "There was a statistically significant decrease of CSF kynurenic acid in patients with epileptic spasms compared to OND (p<0." | 4.12 | Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids. ( Antony, J; Ardern-Holmes, S; Bandodkar, S; Dale, RC; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Innes, EA; Jones, HF; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pires, AS; Tantsis, E; Troedson, C; Tsang, E; Webster, R; Wienholt, L; Yan, J, 2022) |
| "Clinical studies indicate that phenytoin prevents acute post-traumatic seizures but not subsequent post-traumatic epilepsy." | 3.78 | Interictal spikes, seizures and ictal cell death are not necessary for post-traumatic epileptogenesis in vitro. ( Berdichevsky, Y; Dzhala, V; Mail, M; Staley, KJ, 2012) |
| "As a first step in the exploration of this approach, we examined the effect of 4-chloro-kynurenine (4-Cl-KYN), which is converted by astrocytes to the potent NMDA glycine-site antagonist 7-chloro-kynurenic acid (7-Cl-KYNA), on the in vivo epileptiform evoked potentials in the CA1 region of rats with chronic limbic epilepsy (CLE)." | 3.73 | In situ-produced 7-chlorokynurenate has different effects on evoked responses in rats with limbic epilepsy in comparison to naive controls. ( Bertram, EH; Schwarcz, R; Williamson, JM; Wu, HQ; Zhang, DX, 2005) |
| " Continuous microperfusion of the antagonist for the glycine binding site in NMDA receptors 5,7-dichlorokynurenic acid (100 microM) reversed the effect of both glutamate (1 mM) and glycine (1 mM) and suppressed seizures completely in 90% of the animals." | 3.71 | Effect of extracellular long-time microperfusion of high concentrations of glutamate and glycine on picrotoxin seizure thresholds in the hippocampus of freely moving rats. ( Senra-Vidal, A; Sierra-Marcuño, G; Sierra-Paredes, G, 2001) |
| "Kynurenic acid is an endogenous modulator of ionotropic glutamate receptors and a suppressor of the immune system." | 1.56 | Sensitivity of Rodent Microglia to Kynurenines in Models of Epilepsy and Inflammation In Vivo and In Vitro: Microglia Activation is Inhibited by Kynurenic Acid and the Synthetic Analogue SZR104. ( Dulka, K; Földesi, I; Fülöp, F; Gulya, K; Kata, D; Lajkó, N; Mátyás, A; Mihály, A; Szabó, M; Vécsei, L, 2020) |
| "Neuronal loss and gliosis in these animals were examined immunohistochemically." | 1.33 | Kynurenate and 7-chlorokynurenate formation in chronically epileptic rats. ( Bertram, EH; Goodman, JH; Rassoulpour, A; Scharfman, HE; Schwarcz, R; Wu, HQ, 2005) |
| "Kynurenic acid (KYNA) is an antagonist of (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) and N-methyl-D-aspartate (NMDA) receptors and it blocks the glycine site of the NMDA receptor preferentially (IC50 = 7." | 1.30 | Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices. ( Hodgkins, PS; Lee, SC; Scharfman, HE; Schwarcz, R, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.12) | 18.7374 |
| 1990's | 14 (42.42) | 18.2507 |
| 2000's | 8 (24.24) | 29.6817 |
| 2010's | 5 (15.15) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Yan, J | 1 |
| Kothur, K | 1 |
| Innes, EA | 1 |
| Han, VX | 1 |
| Jones, HF | 1 |
| Patel, S | 1 |
| Tsang, E | 1 |
| Webster, R | 1 |
| Gupta, S | 1 |
| Troedson, C | 1 |
| Menezes, MP | 1 |
| Antony, J | 1 |
| Ardern-Holmes, S | 1 |
| Tantsis, E | 1 |
| Mohammad, S | 1 |
| Wienholt, L | 1 |
| Pires, AS | 1 |
| Heng, B | 1 |
| Guillemin, GJ | 1 |
| Guller, A | 1 |
| Gill, D | 1 |
| Bandodkar, S | 1 |
| Dale, RC | 1 |
| Lajkó, N | 1 |
| Kata, D | 1 |
| Szabó, M | 1 |
| Mátyás, A | 1 |
| Dulka, K | 1 |
| Földesi, I | 1 |
| Fülöp, F | 1 |
| Gulya, K | 1 |
| Vécsei, L | 1 |
| Mihály, A | 1 |
| Wu, X | 1 |
| Muthuchamy, M | 1 |
| Reddy, DS | 1 |
| Maciejak, P | 1 |
| Szyndler, J | 1 |
| Turzyńska, D | 1 |
| Sobolewska, A | 1 |
| Kołosowska, K | 1 |
| Krząścik, P | 1 |
| Płaźnik, A | 1 |
| Berdichevsky, Y | 1 |
| Dzhala, V | 1 |
| Mail, M | 1 |
| Staley, KJ | 1 |
| Yamamura, S | 1 |
| Hoshikawa, M | 1 |
| Dai, K | 1 |
| Saito, H | 1 |
| Suzuki, N | 1 |
| Niwa, O | 1 |
| Okada, M | 1 |
| Russo, E | 1 |
| Scicchitano, F | 1 |
| Citraro, R | 1 |
| Aiello, R | 1 |
| Camastra, C | 1 |
| Mainardi, P | 1 |
| Chimirri, S | 1 |
| Perucca, E | 1 |
| Donato, G | 1 |
| De Sarro, G | 1 |
| KAWAMURA, M | 1 |
| MINOJIMA, A | 1 |
| MIZUNO, T | 1 |
| HAYASHI, H | 1 |
| SATO, I | 1 |
| OKINAKA, T | 1 |
| Rho, JM | 1 |
| Wu, HQ | 2 |
| Rassoulpour, A | 1 |
| Goodman, JH | 1 |
| Scharfman, HE | 3 |
| Bertram, EH | 2 |
| Schwarcz, R | 3 |
| Zhang, DX | 1 |
| Williamson, JM | 1 |
| Padmashri, R | 1 |
| Ganguly, A | 1 |
| Mondal, PP | 1 |
| Rajan, K | 1 |
| Sikdar, SK | 1 |
| Mikhaĭlov, IB | 1 |
| Guzeva, VI | 1 |
| Mel'nikova, NV | 1 |
| Rundfeldt, C | 1 |
| Wlaź, P | 1 |
| Löscher, W | 1 |
| Domenici, MR | 1 |
| Longo, R | 1 |
| Sagratella, S | 2 |
| Ofer, A | 1 |
| Muñóz-Hoyos, A | 1 |
| Molina-Carballo, A | 1 |
| Rodríguez-Cabezas, T | 1 |
| Uberos-Fernández, J | 1 |
| Ruiz-Cosano, C | 1 |
| Acuña-Castroviejo, D | 1 |
| Demir, R | 2 |
| Haberly, LB | 2 |
| Jackson, MB | 2 |
| Hodgkins, PS | 1 |
| Lee, SC | 1 |
| Tancredi, V | 1 |
| Biagini, G | 1 |
| D'Antuono, M | 1 |
| Louvel, J | 1 |
| Pumain, R | 1 |
| Avoli, M | 1 |
| Sierra-Paredes, G | 1 |
| Senra-Vidal, A | 1 |
| Sierra-Marcuño, G | 1 |
| Stone, TW | 3 |
| Wu, J | 1 |
| Javedan, SP | 1 |
| Ellsworth, K | 1 |
| Smith, K | 1 |
| Fisher, RS | 1 |
| Namba, T | 1 |
| Morimoto, K | 1 |
| Katayama, K | 1 |
| Inoue, K | 1 |
| Yamada, N | 1 |
| Otsuki, S | 1 |
| Wuarin, JP | 1 |
| Kim, YI | 1 |
| Cepeda, C | 1 |
| Tasker, JG | 1 |
| Walsh, JP | 1 |
| Peacock, WJ | 1 |
| Buchwald, NA | 1 |
| Dudek, FE | 1 |
| Frank, C | 1 |
| de Carolis, AS | 1 |
| Segal, MM | 1 |
| Furshpan, EJ | 1 |
| Malouf, AT | 1 |
| Robbins, CA | 1 |
| Schwartzkroin, PA | 1 |
| Schneiderman, JH | 1 |
| MacDonald, JF | 1 |
| Foster, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for kynurenic acid and Epilepsy
| Article | Year |
|---|---|
Basic science behind the catastrophic epilepsies.
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Corticotropin-Releasing Hormone; Epilepsies | 2004 |
Kynurenic acid antagonists and kynurenine pathway inhibitors.
Topics: Brain Ischemia; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Kynurenic Acid; Kynurenine; Neu | 2001 |
31 other studies available for kynurenic acid and Epilepsy
| Article | Year |
|---|---|
Decreased cerebrospinal fluid kynurenic acid in epileptic spasms: A biomarker of response to corticosteroids.
Topics: 3-Hydroxyanthranilic Acid; Adrenal Cortex Hormones; Animals; Biomarkers; Chromatography, Liquid; Epi | 2022 |
Sensitivity of Rodent Microglia to Kynurenines in Models of Epilepsy and Inflammation In Vivo and In Vitro: Microglia Activation is Inhibited by Kynurenic Acid and the Synthetic Analogue SZR104.
Topics: Animals; Calcium-Binding Proteins; Cells, Cultured; Epilepsy; Excitatory Amino Acid Antagonists; Kyn | 2020 |
Atomic force microscopy investigations of fibronectin and α5β1-integrin signaling in neuroplasticity and seizure susceptibility in experimental epilepsy.
Topics: 4-Aminopyridine; Action Potentials; Animals; Disease Models, Animal; Epilepsy; Excitatory Amino Acid | 2017 |
Is the interaction between fatty acids and tryptophan responsible for the efficacy of a ketogenic diet in epilepsy? The new hypothesis of action.
Topics: Animals; Brain; Diet, Ketogenic; Epilepsy; Fatty Acids; Hypnotics and Sedatives; Implantable Neurost | 2016 |
Interictal spikes, seizures and ictal cell death are not necessary for post-traumatic epileptogenesis in vitro.
Topics: Action Potentials; Animals; Anticonvulsants; Brain Injuries; Cell Death; Epilepsy; Excitatory Amino | 2012 |
ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation.
Topics: Animals; Anticonvulsants; Astrocytes; Caprylates; Cells, Cultured; Convulsants; Disease Models, Anim | 2013 |
Protective activity of α-lactoalbumin (ALAC), a whey protein rich in tryptophan, in rodent models of epileptogenesis.
Topics: Animals; Convulsants; Epilepsy; Epilepsy, Absence; Excitatory Amino Acid Agonists; Excitatory Amino | 2012 |
[CASES OF EPILEPSY WITH SPLENOMEGALY; A NEW CONGENITAL METABOLIC DISORDER].
Topics: Adolescent; Child; Electroencephalography; Epilepsy; Humans; Kynurenic Acid; Lyases; Metabolic Disea | 1964 |
Kynurenate and 7-chlorokynurenate formation in chronically epileptic rats.
Topics: Animals; Astrocytes; Disease Models, Animal; Entorhinal Cortex; Epilepsy; Epilepsy, Temporal Lobe; E | 2005 |
In situ-produced 7-chlorokynurenate has different effects on evoked responses in rats with limbic epilepsy in comparison to naive controls.
Topics: Animals; Disease Models, Animal; Electric Stimulation; Electrodes, Implanted; Electroencephalography | 2005 |
Kynurenate treatment of autaptic hippocampal microcultures affect localized voltage-dependent calcium diffusion in the dendrites.
Topics: Animals; Calcium; Calcium Channels; Cells, Cultured; Dendrites; Diffusion; Epilepsy; Evoked Potentia | 2006 |
[Retardation of an experimental epileptogenic focus in the rat hippocampus by kynurenic acid].
Topics: Animals; Electrodes; Epilepsy; Excitatory Amino Acid Antagonists; Hippocampus; Kynurenic Acid; Male; | 1995 |
Anticonvulsant activity of antagonists and partial agonists for the NMDA receptor-associated glycine site in the kindling model of epilepsy.
Topics: Animals; Anticonvulsants; Cycloserine; Differential Threshold; Epilepsy; Female; Glycine; Kindling, | 1994 |
7-chlorokynurenic acid prevents in vitro epileptiform and neurotoxic effects due to kainic acid.
Topics: Animals; Electrophysiology; Epilepsy; Excitatory Amino Acid Agonists; Hippocampus; In Vitro Techniqu | 1996 |
Pretreatment with L-kynurenine, the precursor to the excitatory amino acid antagonist kynurenic acid, suppresses epileptiform activity in combined entorhinal/hippocampal slices.
Topics: Animals; Anticonvulsants; Buffers; Electrophysiology; Entorhinal Cortex; Epilepsy; Excitatory Amino | 1997 |
Relationships between methoxyindole and kynurenine pathway metabolites in plasma and urine in children suffering from febrile and epileptic seizures.
Topics: 3-Hydroxyanthranilic Acid; Child; Child, Preschool; Circadian Rhythm; Epilepsy; Female; Humans; Infa | 1997 |
Sustained and accelerating activity at two discrete sites generate epileptiform discharges in slices of piriform cortex.
Topics: Animals; Electric Stimulation; Electrophysiology; Epilepsy; Excitatory Amino Acid Antagonists; Fluor | 1999 |
Quantitative differences in the effects of de novo produced and exogenous kynurenic acid in rat brain slices.
Topics: Animals; Buffers; Entorhinal Cortex; Epilepsy; Evoked Potentials; Excitatory Amino Acid Antagonists; | 1999 |
Sustained plateau activity precedes and can generate ictal-like discharges in low-Cl(-) medium in slices from rat piriform cortex.
Topics: Animals; Cerebral Cortex; Chlorides; Culture Media; Electric Stimulation; Electrophysiology; Epileps | 1999 |
Spindle-like thalamocortical synchronization in a rat brain slice preparation.
Topics: 4-Aminopyridine; Animals; Barbiturates; Cerebral Cortex; Cortical Synchronization; Electric Stimulat | 2000 |
Effect of extracellular long-time microperfusion of high concentrations of glutamate and glycine on picrotoxin seizure thresholds in the hippocampus of freely moving rats.
Topics: Animals; Epilepsy; Excitatory Amino Acid Antagonists; Extracellular Space; GABA Antagonists; Glutami | 2001 |
Gamma oscillation underlies hyperthermia-induced epileptiform-like spikes in immature rat hippocampal slices.
Topics: Action Potentials; Anesthetics, Local; Animals; Biological Clocks; Cortical Spreading Depression; El | 2001 |
Effects of strychnine-insensitive glycine receptor antagonist (7-chlorokynurenic acid) on amygdala kindling in rats.
Topics: Amygdala; Analysis of Variance; Animals; Epilepsy; Kindling, Neurologic; Kynurenic Acid; Male; Rats; | 1992 |
Sensitivity of hippocampal neurones to kainic acid, and antagonism by kynurenate.
Topics: Animals; Colchicine; Epilepsy; Hippocampus; In Vitro Techniques; Iontophoresis; Kainic Acid; Kynuren | 1990 |
Synaptic transmission in human neocortex removed for treatment of intractable epilepsy in children.
Topics: 2-Amino-5-phosphonovalerate; Adolescent; Bicuculline; Child; Child, Preschool; Epilepsy; Female; GAB | 1990 |
Inhibitory influence of excitatory amino acid antagonists on penicillin-induced epileptiform bursting in rat hippocampal slices.
Topics: Amino Acids; Animals; Anticonvulsants; Dibenzocycloheptenes; Dizocilpine Maleate; Electric Stimulati | 1990 |
Epileptiform activity in microcultures containing small numbers of hippocampal neurons.
Topics: Animals; Animals, Newborn; Baclofen; Bicuculline; Cells, Cultured; Epilepsy; Evoked Potentials; Hipp | 1990 |
Epileptiform activity in hippocampal slice cultures with normal inhibitory synaptic drive.
Topics: Action Potentials; Animals; Epilepsy; Hippocampus; In Vitro Techniques; Kynurenic Acid; Neural Inhib | 1990 |
Excitatory amino acid blockers differentially affect bursting of in vitro hippocampal neurons in two pharmacological models of epilepsy.
Topics: 2-Amino-5-phosphonovalerate; Action Potentials; Animals; Epilepsy; Guinea Pigs; Hippocampus; In Vitr | 1989 |
Comparison of kynurenic acid and 2-APV suppression of epileptiform activity in rat hippocampal slices.
Topics: 2-Amino-5-phosphonovalerate; Animals; Dose-Response Relationship, Drug; Electrophysiology; Epilepsy; | 1988 |
Involvement of excitatory amino acid receptors in the mechanisms underlying excitotoxic phenomena.
Topics: Action Potentials; Amino Acids, Dicarboxylic; Animals; Cell Survival; Dendrites; Epilepsy; Kynurenic | 1986 |